Familiarity breeds content
Euronext IPO for LSP fund to invest in publicly listed biotechs
European life sciences firm LSP raised €36 million ($52.5 million) last week in an IPO for its first in-house fund to invest in public companies. The firm is capitalizing on investors' familiarity with its venture performance as well as a return in excess of 150% on the public portfolio it has managed for a pension fund since early 2008.
On Wednesday, LSP Life Sciences Fund (Euronext:LSP) sold 360,000 shares at €100 per share.
New shares in the fund, which is similar to a mutual fund, will be issued automatically to future buyers who are unable to purchase them on the open market. That gives LSP the capacity to continue to raise more money over time, Joep Muijrers told Ebb & Flow.
Indeed, the fund raised an additional €3 million by week's end.
Ultimately, the fund is targeting €200-€250 million ($291.6 million-$364.5 million) from European investors. Although they're not the primary target, U.S. investors could allow the fund to grow even larger, Muijrers noted.
LSP has managed public healthcare and biotech investments for pension group APG Investments since 2008.
Muijrers said the investment strategy won't change. The fund will invest primarily in small and mid-cap European biotechs in the €50 million-€1 billion market cap range ($73 million-$1.5 billion). The fund also will invest in the U.S.
The firm marketed the offering itself starting in late February, rather than through a placement agent or underwriter. Initial investors were all institutional asset managers or family offices.
"It wasn't very difficult to raise this fund. Our track record and name as a specialist investor helped," said Muijrers.
"We've been in the business on the private equity side for almost 20 years," LSP's Mark Wegter added. "We've been following these companies for many years, building up an expertise network. We're really leveraging what we've been doing."
Wegter, Muijrers and Geraldine O'Keeffe, who all managed public investments for the APG